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Abstract 
The aim of this paper is to briefly present some aspects of Babesia spp. taxonomy, incidence, clinical signs of their 
infection, and possibilities of prevention, as an introduction to a case study of canine babesiosis presentation. A 7-year-
old Malinois dog was presented in August 2020 with signs of generalized icterus, high body temperature and mustard 
urine, all of them indicating babesiosis. Cytological examination confirmed the large Babesia canis spp., and the 
biochemical investigations revealed renal and hepatic failure. Although the therapeutic protocol included the specific 
antidote, imidocarb dipropionate – Imizol® (0.5 ml/10 kg body weight, in a single dose), fluid therapy, vitamin therapy, 
an antiemetic drug, and supplements for renal and hepatic functions sustaining, the investigated dog died. The post-
mortem investigation revealed generalized icterus. We consider the delaying of dog presentation at vet an important 
factor of this outcome; although an infection with various subspecies of Babesia canis was not excluded, the therapeutic 
intervention would have been the same.  
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Introduction  
Babesiosis is a tick-borne disease caused by various species of Babesia genus parasite. 
This disease is particularly common in dogs, its worldwide distribution drawing a special attention 
(Solano-Gallego and Baneth, 2011; Sudhakara Reddy et al., 2014). Infecting Babesia species in 
dogs were classified in two main groups, large forms being a part of Babesia canis group while 
small species were generally considered as Babesia gibsoni [Fabisiak et al., 2010; Solano-Gallego 
and Baneth, 2011; Zahler et al., 2000(a)]. 
The infection with Babesia canis is attributed to several species of ticks, such as 
Dermacentor reticulatus (Fabisiak et al., 2010; Födvári et al., 2005), while an additional 
transmission path via blood transfusion was reported in dogs for Babesia gibsoni (Stegeman et al., 
2003) or from dog to dog during their fights (Solano-Gallego and Baneth, 2011). 
The diagnosis of babesiosis in dogs is basically done by clinical examination and parasite` 
identification on May-Grünwald Giemsa stained peripheral blood smears (Fabisiak et al., 2010). 
Clinical signs of B. canis infection often include dehydratation, apathy, anorexia or decrease 
appetite, fever (Furlanello et al., 2005; Solano-Gallego et al., 2008); associated anemia has a 
multifactorial component based on plasma volume increasing, erythrocyte retention in the spleen, 
erythrocyte destruction partly due to parasite proliferation (Schetters et al., 1997). Other clinical 
signs may include jaundice or icterus, congested conjunctiva, tachycardia, tachypnea, 
lymphadenopathy, haemoglobinuria, bilirubinuria, with a general condition of lethargy or dullness 
(Fabisiak et al., 2010; Sudhakara Reddy et al., 2014). Splenomegaly, hemolytic anemia, and 
thrombocytopenia were reported in infections with B. gibsoni (Stegeman et al., 2003).  
The diagnosis in peripheral blood smears take into account the size and morphological 
appearance of the intraerythrocytic parasites (Födvári et al., 2005; Muhlnickel et al., 2008). 
Unfortunately, such an examination only provides a presumptive diagnosis of the two groups of 
Babesia, the large and small ones. Different subspecies, although morphologically identical, are 
important to be independently diagnosed due to the difference in their clinical signs (Solano-
Gallego and Baneth, 2011).  




B. gibsoni can be difficult to be detected in red blood cells (RBCs) on peripheral blood 
smear examination, and serologic investigations using fluorescent antibody tests give 
unsatisfactory results in young dogs (1-3 months old) and due to serologic cross-reactivity among 
Babesia spp. (Farwell et al., 1982; Stegeman et al., 2003). Therefore, molecular investigations 
using Polymerase Chain Reaction (PCR) represent the best method to distinct various subspecies 
of this parasite (Cacciò et al., 2002). For example, the results obtained on pairwise identities, 
distance, parsimony, and maximum likelihood analyses of the 18S rRNA gene provided valuable 
information about genetic phylogeny of various types of Babesia [Zahler et al., 2000(a), (b)]. 
Subsequent sequencing of PCR products allows identity to be established by comparison with 
nucleotide sequences already known and recorded in GenBank®, as in the case of B. canis canis, 
accession numbers AY611731.1; AY611732.1; AY611733.1 (Adaszek and Winiarczyck, 2008; 
Födvári et al., 2005). 
For this purpose of taxonomic identification, Cacciò et al. (2002) and Fabisiak et al. (2010) 
reviewed three distinct but morphologically identical subspecies of Babesia canis, such as B. canis 
canis, B. canis rossi, and B. canis vogeli, isolated from dogs in Europe, Africa, and US, 
respectively. The presence of B. canis canis in European isolates and of B. canis rossi in South-
African isolates was confirmed by Schetters et al. (1997b), while B. canis vogeli was detected in 
dogs from Croatia, along with other infectious species such as B. canis canis, B. gibsoni, Theileria 
annae and, surprisingly, with two parasites usually found in horses, Babesia caballi and Theileria 
equi (Beck et al., 2009). In 2004, Matjila et al. confirmed for the first time B. canis vogeli in 
domestic dogs in South Africa; they also reported the presence of B. canis rossi but none of the 
investigated dogs was a carrier of both subspecies together. Solano-Gallego et al. (2008) reported 
the vast majority of B. canis canis infections in Northern Italy, while B. canis vogeli was mainly 
detected in Central and Southern Italy. In 2012, the presence of Babesia vogeli in a clinically 
normal dog in Romania was confirmed for the first time. It was part of a group of five asymptomatic 
dogs whose blood was comparatively tested by PCR technique with that of 11 other dogs with 
symptoms of babesiosis. Investigations of the 18S rRNA segment showed that all dogs with 
symptoms of babesiois were infected with Babesia canis (Ionita et al., 2012). Although the authors 
did not explicitly specify the identified subspecies of Babesia canis, it is well-understood the 
presence of Babesia canis canis, considering the type of vector predominantly found on the 
Romanian territory (Dermacentor reticulatus). They revised the transmission of Babesia vogeli by 
Rhipicephalus sanguineus, commonly called the brown dog tick, while the other Babesia canis 
subspecies, Babesia rossi is transmitted by Haemaphysalis elliptica, with eastern and southern 
Africa location (Beugnet et al., 2019; Fourie et al., 2019). 
Various isolates from infected dogs demonstrated close phylogenetic relationships with 
other Babesia species, such as B. microti, B. rodhaini, B. conradae, B. bigemina, B. divergens, and 
B. odocoilei [Birkenheuer et al., 2004; Camacho et al., 2001; Solano-Gallego and Baneth, 2011; 
Zahler et al., 2000(a), (b)]. In 2008, Muhlnickel et al. firstly identified B. gibsoni in dogs from 
Australia, and in 2009, Beck et al. reviewed that some of Babesia small species appear to be closely 
related to Theileria genus. However, several classical differences, such as the absence of extra-
erythrocytic multiplication (schizogony) in Babesia, or the forming of two daughter cells 
(merozoites) in Babesia comparing to four in Theileria, may contribute to their individualization; 
however, recent opinions do not consider Babesia microti as a Babesia, Babesia equi being already 
designated as Theileria equi (Uilenberg, 2006). 
In conclusion to this introductive review, there is a need for molecular characterization of 
each isolated Babesia parasite in order to perform an appropriate treatment. Large Babesia species 
are commonly treated with imidocarb dipropionate at 5 mg/kg body weight, given intramuscularly 




as a single dose, associated with fluid therapy and even blood transfusion for a good clinical 
response (Irwin and Hutchinson, 1991; Solano-Gallego and Baneth, 2011). Vercammen et al. 
(1995) reported the use of imidocarb dipropionate at 6 mg/kg b.w. They also reported a dog who 
became subclinical chronic carrier of B. canis as a result of a treatment with long acting 
oxytetracycline (20 mg/kg b.w.). Sudhakara Reddy et al. (2014) reported the use of diminazene 
aceturate, 5 mg/kg b.w., single dose, along with supportive and symptomatic therapy in Babesia 
infection of dogs. Both diminazene aceturate and imidocarb dipropionate drugs were reported safe 
to use for haemoprotozoan diseases in the same dosage (Olukunle et al., 2018). 
Small Babesia spp. are considered more resistant to anti parasitic drugs, an incomplete 
elimination of B. gibsoni being translated in chronic carrier survivors (Solano-Gallego and Baneth, 
2011; Stegeman et al., 2003). A treatment with clindamycin (25 mg/kg b.w., per os, at 12 hours, 
for 14 days) of 10 experimentally infected dogs with B. gibsoni was reported to reduce parasitemia 
levels as a result of parasite degeneration, with the improvement of clinical signs of the disease 
(Wulansari et al., 2003). 
Vaccination of dogs against B. canis using soluble parasite antigens (SPA) has been 
reported as a limiting factor in splenomegaly development and an improvement in the immune 
response at 6 days post-vaccination (Schetters et al., 1997). 
The aim of this paper is to review some taxonomic and incidence aspects of Babesia spp. 
and to present a case study of Babesia in dogs whose unfortunate ending shows the importance of 
fast therapeutic intervention until various comorbidities develop.  
 
Material and methods 
Some aspects reported in medical science about Babesia spp. infection, taxonomic 
including, clinical evolution, treatment and prevention were debated basing on 27 scientific papers 
studying. All these were used to provide an overview of a case study of babesiosis in dog, the 
diagnosis of which was established on the basis of usual clinical examination together with 
cytological investigations of May-Grünwald Giemsa stained peripheral blood smear. Blood 
samples were biochemically investigated for the following parameters: serum creatinine, gamma 
glutamyl transferase (GGT), aspartate aminotransferase (ASAT) or (serum) glutamic-oxaloacetic 
transaminase (GOT), alanine aminotransferase (ALAT) or (serum) glutamic-pyruvic transaminase 
(GPT), serum urea [all of these by the method of spectrophotometry], serum potassium and serum 
sodium [both by indirect Ion Selective Electrode (ISE) method]. Post-mortem, a necropsy 
examination was performed in order to observe changes in the organs.  
 
Results and discussions 
In august 2020, a 7-year-old Malinois dog with signs of babesiosis was presented for 
investigations at the Medical Clinic of Veterinary Medicine Faculty of Iași, Romania. Increased 
body temperature (40.60C) and general jaundice, at which mustard urine was associated, firstly 
drew the attention at the clinical examination (Fig. 1).  





Fig. 1. Various clinical aspects in a 7-years-old Malinois dog babesiosis 
 
As a result of cytological examination, Babesia canis was confirmed as parasiting some of 
RBCs (Fig. 2). 
 
  
Fig. 2. Intra erythrocyte Babesia canis. May-Grünwald Giemsa 
 
The therapeutic intervention was prompt, with imidocarb dipropionate - Imizol® specific 
antidote, in a single dose (5 mg/kg b.w. or 0.5ml/10 kg solution 8.5%), together with fluid and 
vitamin therapy. Two days after specific antidote administration, the dog showed polydipsia and 
polyuria.  
Meanwhile, biochemical analyses were performed and their results showed normal values 
but at the lower limit only for serum potassium and serum sodium (3.7 mmol/L and 140 mmol/L, 
respectively). The other investigated parameters exceeded the upper reference limit, such as: serum 
creatinine 2.52 mg/dL vs. 1.8; GGT 147 U/L vs. 10; ASAT 286 U/L vs. 50; ALAT 714 U/L vs. 40; 
serum urea 151.9 mg/dL vs. 26.  
After 5 days, although the clinical evolution was better and the dog started to eat, he died.  
On necropsy, jaundice was generalized, including important organs, such as kidneys, heart, 
and liver (Figure 3).  
 





Fig. 3. Aspect of liver (a) and kidneys (b) on necropsy 
 
From our point of view, the established therapeutic intervention was medically correct. 
The specific antidote for B. canis was chosen, which was confirmed as safe by medical studies. 
The first signs of polydipsia and polyuria led us to think of renal failure, along with that of liver, 
both confirmed by the results of laboratory tests. In order to dilute urea, a sustained fluid therapy 
was performed. A probiotic supplement with S. thermophilus, L. acidophilus, and B. longum was 
administered to support the renal function, as well as a dietary supplement in food, containing 
chitosan. Liver function was sustained with a phospholipid-based supplement, and a maropitant-
based drug (Cerenia®) was administered as antiemetic, the dose of which was correlated with the 
animal`s weight. Therefore, the therapeutic intervention was correctly performed and in a sustained 
way for the healing of the dog. Its dead may be firstly justified by comorbidities developed (such 
as liver and renal failure) in the context of its delayed presentation to the doctor. Although we were 
not able to diagnose subspecies of B. canis, the established treatment is considered effective for all 
large Babesia spp. However, a precise taxonomic classification would have been helpful in 
justifying the clinical evolution.  
 
Conclusions 
Babesia genus includes two main groups, of large and small species, worldwide distributed 
and with a variety of clinical signs in their infection. A 7-year-old dog infected with large Babesia 
canis died although its clinical evolution after a specific antidote improved. Although therapeutic 
protocol was right instituted, comorbidities installed (kidney and liver failure) as a result of its 
delaying to vet consult decided this outcome.  
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